111 related articles for article (PubMed ID: 19433978)
1. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
James E; Waldron-Lynch MG; Saif MW
Anticancer Drugs; 2009 Aug; 20(7):634-8. PubMed ID: 19433978
[TBL] [Abstract][Full Text] [Related]
2. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Chalasani P; Kurtin S; Dragovich T
JOP; 2008 May; 9(3):305-8. PubMed ID: 18469443
[TBL] [Abstract][Full Text] [Related]
3. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Yarchoan M; Myzak MC; Johnson BA; De Jesus-Acosta A; Le DT; Jaffee EM; Azad NS; Donehower RC; Zheng L; Oberstein PE; Fine RL; Laheru DA; Goggins M
Oncotarget; 2017 Jul; 8(27):44073-44081. PubMed ID: 28454122
[TBL] [Abstract][Full Text] [Related]
6. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.
Cantore M; Rabbi C; Fiorentini G; Oliani C; Zamagni D; Iacono C; Mambrini A; Del Freo A; Manni A
Oncology; 2004; 67(2):93-7. PubMed ID: 15539911
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
Burtness B; Thomas L; Sipples R; McGurk M; Salikooti S; Christoforou M; Mirto G; Salem R; Sosa J; Kloss R; Rahman Z; Chung G; Lacy J; Murren JR
Cancer J; 2007; 13(4):257-62. PubMed ID: 17762761
[TBL] [Abstract][Full Text] [Related]
8. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
9. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer.
Kurtz JE; Négrier S; Husseini F; Limacher JM; Borel C; Wagner JP; Prévot G; Bergerat JP; Dufour P
Hepatogastroenterology; 2003; 50(50):567-70. PubMed ID: 12749274
[TBL] [Abstract][Full Text] [Related]
13. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
[TBL] [Abstract][Full Text] [Related]
14. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
15. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Yamada Y; Shirao K; Hyodo I; Arai Y; Denda T; Ambo T; Ohtsu A
Cancer Chemother Pharmacol; 2003 Aug; 52(2):125-30. PubMed ID: 12783200
[TBL] [Abstract][Full Text] [Related]
18. BRCA2 and pancreatic cancer.
Naderi A; Couch FJ
Int J Gastrointest Cancer; 2002; 31(1-3):99-106. PubMed ID: 12622420
[TBL] [Abstract][Full Text] [Related]
19. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
20. Role of BRCA1 and BRCA2 mutations in pancreatic cancer.
Greer JB; Whitcomb DC
Gut; 2007 May; 56(5):601-5. PubMed ID: 16973716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
